<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39390271</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1530-9932</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>10</Day></PubDate></JournalIssue><Title>AAPS PharmSciTech</Title><ISOAbbreviation>AAPS PharmSciTech</ISOAbbreviation></Journal><ArticleTitle>Remote Regulatory Assessments of Bioavailability/Bioequivalence Study Conduct by the Office of Study Integrity and Surveillance.</ArticleTitle><Pagination><StartPage>240</StartPage><MedlinePgn>240</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1208/s12249-024-02967-8</ELocationID><Abstract><AbstractText>The Office of Study Integrity and Surveillance (OSIS) in CDER in FDA coordinates and conducts inspections of sites conducting bioavailability and/or bioequivalence (BA/BE) studies supporting regulatory submissions. In response to travel restrictions during the SARS-CoV-2 (COVID-19) public health emergency, OSIS developed and began conducting remote assessments of BA/BE sites in 2020. This paper provides an overview of remote regulatory assessments (RRAs) and OSIS's approach to RRAs, including procedures, experiences, and examples of findings during RRAs. In addition, as OSIS continues to utilize RRAs while resuming inspections, some areas for improvement are discussed.</AbstractText><CopyrightInformation>© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Javidnia</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Office of Study Integrity and Surveillance, Office of Translational Sciences, Center for Drug Evaluation and Research, United States Food and Drug Administration, United States Department of Health and Human Services, 10903 New Hampshire Ave, Silver Spring, Maryland, 20993-0002, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irier</LastName><ForeName>Hasan A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Office of Study Integrity and Surveillance, Office of Translational Sciences, Center for Drug Evaluation and Research, United States Food and Drug Administration, United States Department of Health and Human Services, 10903 New Hampshire Ave, Silver Spring, Maryland, 20993-0002, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kassim</LastName><ForeName>Sean</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Office of Study Integrity and Surveillance, Office of Translational Sciences, Center for Drug Evaluation and Research, United States Food and Drug Administration, United States Department of Health and Human Services, 10903 New Hampshire Ave, Silver Spring, Maryland, 20993-0002, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Seongeun Julia</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Office of Study Integrity and Surveillance, Office of Translational Sciences, Center for Drug Evaluation and Research, United States Food and Drug Administration, United States Department of Health and Human Services, 10903 New Hampshire Ave, Silver Spring, Maryland, 20993-0002, USA. seongeun.cho@fda.hhs.gov.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AAPS PharmSciTech</MedlineTA><NlmUniqueID>100960111</NlmUniqueID><ISSNLinking>1530-9932</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001682" MajorTopicYN="Y">Biological Availability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014486" MajorTopicYN="Y">United States Food and Drug Administration</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013810" MajorTopicYN="Y">Therapeutic Equivalency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">OSIS</Keyword><Keyword MajorTopicYN="N">bioavailability</Keyword><Keyword MajorTopicYN="N">bioequivalence</Keyword><Keyword MajorTopicYN="N">inspection</Keyword><Keyword MajorTopicYN="N">remote regulatory assessment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>0</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>23</Hour><Minute>38</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39390271</ArticleId><ArticleId IdType="doi">10.1208/s12249-024-02967-8</ArticleId><ArticleId IdType="pii">10.1208/s12249-024-02967-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>U.S. Department of Health and Human Services, Food and Drug Administration. Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities During the COVID-19 Public Health Emergency Guidance for Industry. [Online]. 2023 [cited 2023 04 17. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/remote-interactive-evaluations-drug-manufacturing-and-bioresearch-monitoring-facilities-during-covid .</Citation></Reference><Reference><Citation>U.S. Department of Health and Human Services, Food and Drug Administration. Conducting Remote Regulatory Assessments Questions and Answers Draft Guidance for Industry. [Online]. 2024 [cited 2024 January 26. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/conducting-remote-regulatory-assessments-questions-and-answers .</Citation></Reference><Reference><Citation>Ayalew K, Sellers J, Kronstein PD, Muldowney L, Gebbia E, Mulinde J, et al. The United States Food and Drug Administration’s Innovative Alternative Tools to Evaluate Good Clinical Practice During the COVID-19 Public Health Emergency. J Soc Clin Data Manag. 2023;2(2):1–7.</Citation><ArticleIdList><ArticleId IdType="doi">10.47912/jscdm.216</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Health and Human Services, Food and Drug Administration. BIMO Inspection Metrics. [Online]. 2024 [cited 2024 05 21. Available from: https://www.fda.gov/science-research/clinical-trials-and-human-subject-protection/bimo-inspection-metrics .</Citation></Reference><Reference><Citation>U.S. Health and Human Services, Food and Drug Administration. Chapter 48 - Bioresearch Monitoring. [Online]. 2018 [cited 2024 04 11. Available from: https://www.fda.gov/media/112533/download .</Citation></Reference><Reference><Citation>U.S. Department of Health and Human Services, Food and Drug Administration. Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities Guidance for Industry Draft Guidance. [Online]. 2023 [cited 2024 March 21. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/remote-interactive-evaluations-drug-manufacturing-and-bioresearch-monitoring-facilities .</Citation></Reference><Reference><Citation>U.S. Department of Health and Human Services, Food and Drug Administration. M10 Bioanalytical Method Validation and Study Sample Analysis. [Online]. 2022 [cited 2024 February 1. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m10-bioanalytical-method-validation-and-study-sample-analysis .</Citation></Reference><Reference><Citation>U.S. Department of Health and Human Services, Food and Drug Administration. Immunogenicity Assessment for Therapeutic Protein Products. [Online]. 2014 [cited 2024 February 1. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/immunogenicity-assessment-therapeutic-protein-products .</Citation></Reference><Reference><Citation>U.S. Department of Health and Human Services, Food and Drug Administration. Product-Specific Guidances for Generic Drug Development. [Online]. 2022 [cited 2024 February 1. Available from: https://www.fda.gov/drugs/guidances-drugs/product-specific-guidances-generic-drug-development .</Citation></Reference><Reference><Citation>U.S. Department of Health and Human Services, Food and Drug Administration. Bioanalytical Method Validation Guidance for Industry. [Online]. 2018 [cited 2024 February 1. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-guidance-industry .</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>